Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bedoradrine - Kissei Pharmaceutical/MediciNova

Drug Profile

Bedoradrine - Kissei Pharmaceutical/MediciNova

Alternative Names: Bedoradrine sulfate; KUR-1246; MLN-221; MN-221

Latest Information Update: 28 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; MediciNova
  • Class Acetamides; Antiasthmatics; Ethanolamines; Naphthalenes; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute asthma

Highest Development Phases

  • Phase II Acute asthma; Preterm labour
  • No development reported Chronic obstructive pulmonary disease; Status asthmaticus

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in USA (IV, Infusion)
  • 09 Feb 2018 Phase-II clinical trials in Preterm labour in USA (IV) before February 2018 (Kissei pipeline, February 2018)
  • 07 Feb 2018 Bedoradrine is available for licensing as of 12 Feb 2018. www.medicinova.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top